Strong Sales Growth and Strategic Initiatives Justify Buy Rating for NeuroPace

TipRanksMay 29 17:45

NeuroPace, Inc.'s (NASDAQ:NPCE) Top Owners Are Private Equity Firms With 47% Stake, While 24% Is Held by Institutions

Yahoo FinanceMay 27 19:17

Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20

Lake Street analyst Frank Takkinen maintains $NeuroPace(NPCE.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 38.5% and a tot

Futu NewsMay 23 21:33

NeuroPace to Participate in Two Healthcare Conferences in May

MOUNTAIN VIEW, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will participate in

GlobeNewswireMay 15 04:05

NeuroPace, Inc. (NASDAQ:NPCE) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 13 22:46

Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating

NeuroPace (NPCE) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $9.50 to $20.

MT NewswiresMay 13 18:53